Anti-TPA Tissue Plasminogen Activator antibody (ab28219)

Submit a review Q&A (3)References (2)

Key features and details

  • Rabbit polyclonal to TPA Tissue Plasminogen Activator
  • Suitable for: ELISA
  • Reacts with: Human
  • Isotype: IgG

Overview

  • Product name

    Anti-TPA Tissue Plasminogen Activator antibody
    See all TPA Tissue Plasminogen Activator primary antibodies

  • Description

    Rabbit polyclonal to TPA Tissue Plasminogen Activator

  • Host species

    Rabbit

  • Tested applications

    Suitable for: ELISAmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Recombinant full length TPA Tissue Plasminogen Activator protein (Human).

Properties

Applications

Our Abpromise guarantee covers the use of ab28219 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/100000.

Target

  • Function

    Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.

  • Tissue specificity

    Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.

  • Involvement in disease

    Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.

  • Sequence similarities

    Belongs to the peptidase S1 family.
    Contains 1 EGF-like domain.
    Contains 1 fibronectin type-I domain.
    Contains 2 kringle domains.
    Contains 1 peptidase S1 domain.

  • Domain

    Both FN1 and one of the kringle domains are required for binding to fibrin.
    Both FN1 and EGF-like domains are important for binding to LRP1.
    The FN1 domain mediates binding to annexin A2.
    The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.

  • Post-translational
    modifications

    The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
    Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
    N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
    Characterization of O-linked glycan was studied in Bowes melanoma cell line.

  • Cellular localization

    Secreted > extracellular space.
  • Information by UniProt

  • Database links

    • Alternative names

      • Alteplase antibody
      • DKFZp686I03148 antibody
      • Plasminogen activator tissue antibody
      • Plasminogen activator tissue type antibody
      • PLAT antibody
      • Reteplase antibody
      • t PA antibody
      • T Plasminogen Activator antibody
      • t-PA antibody
      • T-plasminogen activator antibody
      • Tissue plasminogen activator (t PA) antibody
      • Tissue type plasminogen activator antibody
      • Tissue-type plasminogen activator chain B antibody
      • tPA antibody
      • TPA_HUMAN antibody
      • TPA1 antibody
      see all

    Protocols

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    References (2)

    Publishing research using ab28219? Please let us know so that we can cite the reference in this datasheet.

    ab28219 has been referenced in 2 publications.

    • Maynadier M  et al. Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. Int J Oncol 43:1683-90 (2013). PubMed: 24026424
    • Chenau J  et al. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 8:4579-91 (2009). WB ; Human . PubMed: 19639960

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    1-3 of 3 Abreviews or Q&A

    Question

    Please let me know the concentration of the above antibody.

    Read More
    Answer

    Thank you for contacting us.

    This antibody has not been purified and therefore, its concentration has not been determined. However we estimate that its concentration will be in the region of 1-10 mg/ml.

    I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

    Free Rabbit monoclonal antibody with any purchase of a primary antibody, while stocks last! Quote “RABMAB-XBSMG” in your next primary antibody order. For more information, visit the following link: https://www.abcam.com/index.html?pageconfig=resource&rid=15447

    Read More

    Question

    Thank you very much for your answer. I hope they are still ok as well. We do see indeed a bit more background than 2 weeks ago, but it might also be due to the sample. We blot with iBlot (invitrogen), block the mamabrane for 4 h and incubate with primary antibody overnight in the fridge without shaking. Further western blot is performed wth WesternBreeze kit from invitrogen, so after incubation with each anitbody there are 3 short washes. We could do additional washing step between applying antibodies. If you have any tips, you are welcome.  

    Read More
    Answer

    I do have a few recommendations that might help. One thing you can do is block the membranes overnight at four degrees Celsius which can help reduce background. Also, incubating the primary antibody with blocking solution that also has 0.01% tween 20 can also help reduce non-specific binding. Adding tween to your washing fluid is also effective. Lastly, I would recommend that you use a semi dry transfer method or a full immersion transfer. We have heard from some customers that using the iBlot system can also contribute to background staining on the blot. I hope that you find this information helpful. Please feel free to contact us again should you have further questions about this antibody or any of the products in our catalogue.    

    Read More

    Question

    I'm writing with question regarding storage of primary antibodies AB 28219. Around 5 weeks ago we boght 7 vials from you. Package was labelled with storage conditions of 2-8 degrees and this is how they were stored for 5 weeks. Now we have found the information that antibodies should be aliquoted and stored at -80 degrees. Can you speculate if storage at 2-8 degress for 5 weeks has seviere implications on the stability/sensitivity and performance of this antibodies ?  

    Read More
    Answer

    Thank you for contacting Abcam. I am sorry for the confusion about the storage conditions. I think the antibodies will most likely be fine if you can aliquot them and get them in a freezer. We have done several tests with the stability of our antibodies and know it to be quite good. The recommended storage on the datasheet is important but more so for long term storage. Having said that you may notice a bit more background or non-specific staining with these antibodies, but that issue can usual be solved by adjusting your blocking, washing or primary incubation methods.    

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com